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Objective: Sphingosine-1-phosphate (S1P) is a natural metabolite that is 
cardioprotective, but its effects on endothelial glycocalyx damage during ischemia-
reperfusion (I/R) are unknown. Therefore, we investigated the effect of S1P on the 
endothelial glycocalyx during I/R. 
Methods: Isolated hearts from Wistar rats were perfused on a Langendorff system 
with Krebs-Henseleit buffer and pre-treated with S1P (10 nM) before I/R. Infarct size 
was measured by triphenyl tetrazolium chloride staining (n³6 per group). Cardiac 
edema was assessed by calculating total water content (n=7 per group) and 
histologically quantifying the interstitial compartment (n³3 per group). The post-
ischemic coronary release of syndecan-1 was quantified using ELISA. Syndecan-1 
immunostaining intensity was assessed in perfusion-fixed hearts (n³3 per group).    
Results: Pre-treatment with S1P decreased infarct size in isolated hearts subjected 
to I/R (P=0.01 vs. I/R). However, S1P had no effect on syndecan-1 levels in the 
coronary effluent or on the intensity of the syndecan-1 immunostaining signal in 
cardiac tissue. Heart total water content was not significantly different between control 
and ischemic groups but was significantly decreased in hearts treated with S1P alone. 
Conclusion: These results suggest that S1P-induced cardioprotection against I/R 
injury is not mediated by the maintenance of syndecan-1 in the endothelial glycocalyx.   




I/R: ischemia reperfusion 
LVEDP: left ventricular end diastolic pressure 
LVP: left ventricular pressure 
LVSP: left ventricular systolic pressure 
NFR: Net filtration rate 
PFA: paraformaldehyde 
RPP: Rate pressure product 
S1P: Sphingosine-1-phosphate 





Ischemic heart disease is a leading cause of deaths in many countries, ahead of 
other non-communicable diseases such as cancer, stroke and respiratory diseases. 1 
Ischemia can cause cardiac tissue infarction and cell damage. Paradoxically, 
although reperfusion of ischemic tissue is important to improve the survival of the 
tissues and prevent irreversible cellular injury, it may lead to more cellular damage 
than that caused by ischemia alone, a phenomenon commonly referred to as 
ischemia/reperfusion (I/R) injury. 2 Although I/R injury is mainly characterized as a 
disease of cardiomyocytes, the coronary vasculature is a major target of the injury. 3  
 
Coronary vessels are lined by endothelial cells which play a key role in maintaining 
vascular tone, regulating hemostasis, and regulating inflammatory processes. The 
luminal surface of these endothelial cells is covered by the glycocalyx, a thin 
carbohydrate-rich layer. The endothelial glycocalyx is approximately 0.2 – 0.5 µm thick 
in small capillaries and becomes thicker as the vascular diameter increases. 4,5 The 
glycocalyx is composed of glycoproteins, proteoglycans and soluble components. 6 
Proteoglycans consist of negatively charged sulphated glycosaminoglycans, such as 
heparan sulphate, attached to core proteins such as syndecans. 
The glycocalyx provides essential functions necessary for vascular homeostasis. It 
regulates vascular permeability, 4,7 acts as a physical barrier between the cell 
adhesion molecules and blood cells, 8 and it acts as a mechanotransducer which 
converts shear stress of blood flow into shear-dependent endothelial responses. 5,9-11 
The glycocalyx functions are dependent on the structural integrity of the glycocalyx 
and the health status of blood vessels. However, the glycocalyx is very delicate and is 
easily damaged during I/R injury, 12 resulting in increased vascular permeability. 
Sphingosine-1-phosphate (S1P) is a membrane phospholipid metabolite that has 
been shown to protect the heart against I/R 11,13,14, and protects against shedding of 
the glycocalyx after removal of plasma albumin in rat fat pad endothelial cells 15, during 
trauma-hemorrhagic shock, 16 during hemorrhagic shock and resuscitation 17 and 
during tumour cell adhesion. 18 Its concentration in the plasma and serum ranges from 
0.3 - 0.5 µM and approximately 90% is bound to serum proteins, mainly high-density 
lipoproteins, serum albumin and low-density lipoproteins. 19 These proteins carry S1P 
to the endothelial cells to maintain vascular permeability. 20 Furthermore, S1P can 
regulate and induce synthesis of glycocalyx components after their shedding as 
previously reported in rat fat-pad endothelial cells. 21,22 However, this ability of S1P to 
stabilize and replenish the endothelial glycocalyx has not been shown in a whole organ 
model in the context of I/R injury. Therefore, we hypothesize that S1P-induced 
cardioprotection, at concentrations previously shown to decrease infarct size, is 
mediated by modulation of the glycocalyx during I/R in the isolated rat heart. 
 
In this study we use the well characterized Langendorff perfused rat heart 23,24 to 
assess the effect of S1P on one particular glycocalyx component, syndecan-1, 
during an ischemia reperfusion insult. These experiments will incorporate the 
changes to the Langendorff perfusion system, used by other groups in the guinea pig 
25-27, which allow collection of the coronary effluent for measurement of glycocalyx 
components. This model has proven to be an effective model previously for the 
assessment of a compounds ability to protect the endothelial glycocalyx during 
ischemia reperfusion 25,26.   
Materials and Methods 
Animals 
Adult male Wistar rats (weight 250 - 300 g) were used in the present study. All 
experimental procedures were approved by the Faculty of Health Sciences Animal 
Ethics Committee, University of Cape Town (Protocol AEC REF NO: 014/012) and 
were performed in compliance with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (National Research Council, 
National Press 2011). Animals were obtained from University of Stellenbosch Animal 
unit and housed under standardized conditions (12-hour light-dark cycle and 
temperature of ~23 οC) at an animal facility at the University of Cape Town. Animals 
had access to food and water ad libitum.    
 
Heart Isolation and Langendorff Perfusion 
Hearts were isolated and perfused on a Langendorff system. Briefly, rats were 
anaesthetized with sodium pentobarbitone (70 mg/kg, i.p.) and injected with heparin 
(500 IU, i.p.). Hearts were excised rapidly, arrested in cold Krebs-Henseleit buffer (K-
H) (4οC), and mounted on the Langendorff retrograde perfusion system via 
cannulation of the aorta. The hearts were perfused with K-H buffer (comprised of mM 
118.5 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.8 CaCl2, 1.2 MgSO4, 11 glucose, 
pH 7.4), and equilibrated with 95% O2: 5% CO2 throughout the protocol at constant 
pressure (74 mmHg) and temperature (37 οC). 
Hemodynamic parameters were measured using a pressure transducer (MLT0699, 
ADInstruments, Australia) connected to a water-filled balloon which was inserted into 
the left ventricle. This transducer was connected to a Power Lab 4/30 data acquisition 
system (ADInstruments, Australia) via a Bridge Amplifier (ML221, ADInstruments, 
Australia). The data were recorded and digitized using Lab chart software version 7 
(ADInstruments). The left ventricular end diastolic pressure was adjusted between 4 
and 12 mmHg at the beginning of the protocol. The pulmonary artery was cannulated 
to allow for measurement of coronary flow rate and collection of coronary venous 
effluent. Coronary venous effluent was stored for measurement syndecan-1 levels. 
 
Treatment Protocol 
All hearts were stabilized for 20 minutes and divided according to treatment and 
induction of global ischemia. Four groups were used (N≥ 16 per group) as described 
in Figure 1: Control group (n=16); hearts were infused with the vehicle DMSO (1:10000 
diluted in K-H) for 7 minutes, and then perfused with K-H for 90 minutes. I/R group 
(n=17); hearts were infused with DMSO for 7 minutes, followed by 10 minutes washout 
with K-H buffer, 11,13 thereafter exposed to 20 minutes global ischemia followed by 60 
min reperfusion. I/R +S1P group (n=16); Hearts were infused with S1P (10 nM) for 7 
minutes, followed by 10 minutes washout, exposure to 20 minutes global ischemia 
followed by 60 min reperfusion. S1P group (n=17); Hearts were infused with S1P (10 
nM) for 7 minutes followed by perfusion with K-H for 90 minutes. 
An infusion pump (Graseby 2100, Medical Smith, UK) was used to infuse S1P and 
DMSO into the heart through a 3-way tap connected to both the aortic cannula and K-
H reservoir. The infusion speed was adjusted to 1/10 of the coronary flow to minimise 
alteration of the main perfusion inflow.  
 
Figure 1: Schematic representation of the Langendorff perfusion protocol. I/R= 




Various cardiac parameters were measured throughout the experiment, including left 
ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), 
heart rate, coronary flow and left ventricular developed pressure (LVDP: the 
difference between left ventricular systolic and left ventricular end-diastolic 
pressure). Rate pressure product (RPP) was calculated as LVDP × heart rate, and 
functional recovery was expressed as a percentage of baseline. The coronary flow 
rate was measured by timed collection of coronary effluent through cannulation of 
the pulmonary artery. The transudate was collected from the apex of the heart and 
net filtration rate (NFR) was calculated as the ratio between the transudate and 
effluent flow rate. 
Infarct Size Analysis 
In line with other studies showing S1P induced cardioprotection 11,13,14, at the end of 
the perfusion protocol, infarct size was determined as described previously 11. 
Briefly, hearts (n≥ 6 per group) were frozen and sectioned into slices of 
approximately 2 mm from apex to base and the slice nearest the base of the heart 
was omitted.  Slices were incubated in 1% Triphenyl tetrazolium chloride in 
phosphate buffer at 37 οC (pH 7.4) for 20 minutes. Slices were fixed in 10% formalin 
solution overnight. Heart slices were laid out in order between two glass sheets and 
digitally scanned on a flatbed scanner (CanoScan LDE 110, Vietnam). Total tissue 
area and infarct area were measured using ImageJ software, 28 as adapted from 
Shakkotai 29. Briefly, using the polygon selection function of the software, total 
ventricular area (area at risk) was measured by trimming and cutting the unwanted 
segments including the LV cavity and anything outside the ventricles, and then 
tracing the outline of the slices. Once the outline was traced, it was possible to select 
everything inside the tracing and measure the total area of the ventricle using the 
“measure” tool.  Then a Red-Green-Blue split function was performed. The green 
channel was used to highlight the infarcted tissue and the cumulative infarcted area 
was obtained by selecting the highlighted infarcted tissue and again using the 
“measure” tool. Infarct size was expressed as a percentage of the total ventricular 
area. 
 
Assessment of Cardiac Edema 
After 30 minutes reperfusion, hearts (n=7 per group) were weighed to obtain wet 
weight and weighed again after 24 hours drying in the oven at 60 οC to obtain dry 
weight. To quantify formation of edema, these values were used to calculate total 
water weight (TWC)  per gram of dry tissue weight using the formula below; 
TWC = (wet weight-dry weight)/dry weight.  
 
Extracellular edema was quantified by histological investigation.  
 
Quantification of the Glycocalyx Components in Cardiac Effluent 
In all groups, samples of coronary effluent were collected through the pulmonary artery 
over 10 minutes after the onset of reperfusion and used for assessing shedding of 
syndecan-1 (n³7). Samples were prepared as previously described by Annecke et 
al.25 Briefly, samples of 2 ml each were concentrated to 150 – 200 µL with 10 kDa cut-
off ultrafilters centrifugal unit (Millipore, Billerica, MA, USA). Samples were aliquoted 
(50 µL) and used to determine syndecan-1 by ELISA (Diaclone research, Besancon, 
France).  
Histological Investigation 
Hearts from a subset of the animals (n=3 per group) were perfusion-fixed immediately 
at the end of the treatment protocol with 4% paraformaldehyde (PFA) in PBS (pH 7.4) 
for 10 min at room temperature using an infusion pump (Graseby 2100, Medical Smith, 
UK). Thereafter they were immersion-fixed in 4%PFA in PBS overnight at 4 ºC and 
were processed to wax. For immunostaining of syndecan-1, paraffin embedded 
sections (6 µm thickness, 3 sections/heart) were mounted on coated microscope glass 
slides, deparaffinised, rehydrated to water, washed in PBS and immunoblocked in % 
BSA in PBS/ 0.1% Triton X-100 for 2 hours at room temperature. Sections were 
incubated in rabbit monoclonal [EPR6454] syndecan-1 primary antibody (ab216458, 
Abcam 1:500) overnight at 4o C, washed in PBS/ 0.1% Tween-20 and incubated in 
goat anti-rabbit HRP- linked secondary antibody (ab6721, Abcam 1:250) for 1 hour at 
room temperature.  Sections were incubated in Vector DAB substrate (DAB 
Peroxidase kit, Cat.No.SK-4100, Vector, Burlingame, CA) for 6 minutes (based on 
prior optimisation of the DAB signal), dehydrated, cleared and mounted with Dibutyl 
phthalate-DPX (Sigma). Negative controls were performed by excluding the primary 
antibody only or excluding both antibodies to determine any non-specific cross-
reactivity with the secondary antibody or endogenous peroxidase respectively. 
Tile scans of each section were captured using a 40X objective lens on a Virtual Slide 
Microscope System (VS120-L100-W, Olympus, Japan). The left ventricular area was 
identified on the tile-scanned images and 20 blood vessels per section x 3 sections 
per heart (arteries and veins excluding small capillaries) were visually scored to 
assess the relative staining intensity of syndecan-1. The scoring system to evaluate 
the presence of syndecan-1 was based on a modification of that used by Kliment et 
al.30 from a score of 0 - 2 to that of 0 - 3 for this study (viz. staining intensity was  scored 
as 0 = no staining, 1 = mild staining, 2 = moderate staining, 3 = intense staining) 
(Figure 2) .    
Figure 2: Scoring of syndecan-1 immunostaining. Scoring categories according to 
staining intensity of the vessel wall are shown as described in image analysis section 
(bar = 50µm); (A) Score 0 = no staining, (B) Score 1 = mild staining, (C) Score 2 = 
moderate staining, (D) Score 3 = intense staining .  
Paraffin sections (5 µm thickness (3 sections/heart)) were stained with Haematoxylin 
and Eosin (H&E) for histological analysis of cardiac edema. Sections were viewed and 
photographed using the 20X objective lens on a Zeiss Axioskop 2 Mot plus light 
microscope (Carl Zeiss, Germany), fitted with the AxioCamHR camera controlled by 
Axiovision 4.7 software (Carl Zeiss, Germany). Images from three regions of the left 
ventricle (as shown in Figure 3 A) of each section (3 sections/ heart) were analysed. 
The extracellular compartment (i.e. any space outside the cardiomyocytes) was 
measured by thresholding (Figure 3 B and C) using ImageJ software 28 and the data 
expressed as a percentage of total area of the field of the image. 
 
 
Figure 3: Histological Analysis of Oedema: A) Hematoxylin and Eosin(H&E)-stained 
paraffin-embedded section from one heart.  Boxes 1, 2 and 3 represent the site of 
images captured (bar = 500µm).  (B) Higher magnification of the H&E-stained section 
of selected region (as shown in A) of the left ventricle of one heart(bar = 50µm), and 
(C) is the same image as (B) showing thresholding of the extracellular space (red) 
using ImageJ software (bar = 50µm). 
     
Statistical Analysis 
All data were presented as the mean ± SEM. Data was subjected to Shapiro-Wilk 
normality tests. Comparisons between multiple groups were performed using one-
way ANOVA, and repeated measures ANOVA were used for measurements in a 
single group measured more than one time. Post-hoc tests were performed using 
Tukey's test. A value of P<0.05 was considered to be statistically significant. 
GraphPad Prism statistical software version 7 was used to conduct the analysis 
(GraphPad Prism, USA). For the semiquantitative analysis of ordinal data of relative 
Syndecan-1 staining intensity, no statistical analysis was done and only the pattern 




Effect of S1P on Infarct Size 
 
Rat hearts exposed to the ischemic protocol alone had significantly increased infarct 
sizes (32.34 ± 4.08%, n=7) compared to control hearts (17.33 ± 1.59%, n=6, P= 0.04, 
control vs. I/R) and hearts treated with S1P alone (16.06 ± 4.07, n=7, P=0.02, S1P vs. 
I/R). Treatment with S1P before ischemia (I/R+S1P) significantly decreased infarct 
size to 14.17± 4.35 (P= 0.01, n=6, I/R+S1P vs. I/R) (Figure 4).  
Figure 4: Effect of S1P on infarct size of isolated hearts subjected to 20 minutes 
ischemia and 1 hour reperfusion: (A) Representative images of cross sectional 
slices of the ventricular myocardium stained with TTC. Slices from one heart per group 
are shown. Since TTC stains live tissue red, infarct is seen as paler tissue. (B) Infarct 
size is expressed as a percentage of total ventricular area (*P<0.05 vs. I/R. N≥6/ 




Effect of S1P on Hemodynamic Parameters in Isolated Perfused Hearts 
The hemodynamic data of the isolated hearts subjected to 20 minutes ischemia and 
60 minutes reperfusion, with or without S1P treatment, were recorded at different time 
points during the protocol for all groups (Figure 5). At the end of the protocol, control 
hearts had postperfusion LVDP of 40.66 ± 2.02 mmHg and LVEDP of 26.15 ± 3.82 
mmHg. I/R caused a significant decrease in LVDP 18.19 ± 4.78 mmHg, (P=0.02 vs. 
control) and an increase LVEDP of 61.37 ± 5.32 mmHg (P<0.0001 vs. control). S1P 
treatment before ischemia did not improve recovery of LVDP (15.51 ± 2.06 mmHg vs. 
I/R, P>0.05 n.s) or LVEDP (69.49 ± 3.62 mmHg vs. I/R, P>0.05 n.s). In S1P treated 
hearts that were not subjected to ischemia, LVDP and LVEDP were not significantly 
different from the control (LVDP: 39.83 ± 4.24 mmHg P=0.99 vs. control; LVEDP: 
12.98 ± 1.86 mmHg, P=0.1 vs. control). Heart rate, coronary flow, net filtration rate, 
and RPP were not significantly different between the groups at the end of reperfusion. 
The baseline hemodynamic parameters measured at the end of 20 minutes 
stabilization were not significantly different between the groups.  However, in every 
single group there was a significant decrease in LVDP and CF by the end of 
reperfusion compared to the values measured at the end of stabilization (P<0.0001 at 
the end vs. baseline). All groups except the S1P perfusion group showed a significant 
increase in LVEDP by the end of reperfusion, compared to the baseline values 
(P<0.001). HR was not significantly different at the end of perfusion in comparison to 
the baseline values in each group (P>0.05). The control and ischemia alone groups 
demonstrated a significant increased net filtration rate by the end of reperfusion 
compared to baseline (P<0.05). Similar increases were not seen for the S1P treated 
groups. Also, the ischemic groups (I/R, I/R+S1P) had a significant difference in net 
filtration rate early after reperfusion, compared to the S1P perfusion group (P≤0.002) 
(Figure 5E). 
 
Figure 5: Effect of S1P on hemodynamic parameters of isolated hearts for all 
groups. Graphs A-E show the changes in (A) left ventricular developed pressure 
(LVDP), (B) left ventricular end diastolic pressure (LVEDP), (C) heart rate (HR), (D) 
coronary flow (CF), (E) net filtration rate (NFR) over time in each group and (F) 
shows rate pressure product (RPP) for each group calculated after 60 minutes 
reperfusion and expressed as percentage of the baseline. Control group ( , blue, 
n=6), Ischemia/reperfusion group( I/R , red, n=7), Ischemia/reperfusion +S1P 
(I/R+S1P , black,n=6), S1P perfusion ( , green, n=7).* P<0.05, **P<0.01 vs. 
control. +P<0.05, ++P<0.01 vs. S1P perfusion & P<0.05 I/R vs. I/R+S1P.  
 
Effect of S1P on Cardiac Edema in the Isolated Perfused Heart 
Mean TBW of isolated hearts were measured after 20 minutes ischemia (or equivalent 
perfusion for control groups) and 30 minutes reperfusion with or without S1P 
treatment.  
Mean TBW in control hearts was 7.24 ± 0.09.  The ratio was not significantly different 
for either of the ischemic groups (Ischemia: 6.61 ± 0.20, Ischemia +S1P: 6.76 ± 0.21, 
P>0.05 vs. Control), however S1P treatment alone caused a significant decrease in 
the ratio (6.41 ± 0.28, P=0.04).  
The ratio of interstitial area (i.e. excluding cardiomyocytes) to the total area of the 
image field was measured to quantify cardiac edema. In the control hearts, the 
interstitial area was 37.06 ± 0.95 % and increased in the ischemic group (43.48 ± 1.07 
%). Although not tested for significance, treatment with S1P before ischemia tended 
to decrease interstitial area to control levels (37.43 ± 0.96 %). S1P treatment without 
ischemia had no effect on the interstitial area (37.96 ± 1.53 %) (Figure 6).   
Figure 6: Cardiac edema in H&E-stained wax sections of the left ventricle. 
Morphological features of the cardiac tissue show a distinct increase in extracellular 
edema in the I/R group.  One section from a heart in each group is shown. (bar = 
50µm). I/R= Ischemia-reperfusion, S1P= sphingosine-1-phosphate. H&E= 
Haemotoxylin & Eosin 
 
 
Effect of S1P Treatment on Syndecan-1 Shedding 
Shedding of the glycocalyx was assessed by measuring the level of syndecan-1 in the 
coronary effluent using ELISA. Syndecan-1 levels in the coronary effluent of the hearts 
subjected to 20 minutes global ischemia followed by reperfusion (10.22 ± 1.39 ng/ml, 
n=10) were significantly higher than that detected in the control group (3.92 ± 0.76 
ng/ml, P=0.0002, n=10). Pretreatment with S1P before ischemia had no significant 
effect on the shedding of syndecan-1 (8.59 ± 1.14 ng/ml, P=0.7 vs. I/R, n=7). The 
group treated with S1P without ischemia had similar syndecan-1 levels to the control 
group (3.24 ± 0.47 ng/ml, P=n.s vs. control, n=9) and was significantly different from 
the ischemic groups (P<0.0001 vs. I/R, P=0.0056 vs. I/R+S1P) (Figure 7A).  
  
Figure 7: Syndecan-1 levels in response to ischemia and S1P treatment A) 
Quantitative measurement of syndecan-1 release in the coronary effluent of isolated 
hearts. *P< 0.05, ***P<0.001 vs. control, ##P< 0.01, ###P<0.001 vs. S1P perfusion 
group (n³7 per group). B) Low magnification of chromogenic staining of syndecan-1 
in paraffin-embedded sections from the left ventricle of one heart per group. Staining 
is more intense in non-ischemic hearts (control and S1P) than in ischemic hearts (I/R 
and I/R+S1P). The slight increase in staining intensity in the regions close to the 
epicardium and endocardium (arrows) is due to higher numbers of capillaries in the 
cross-sectional profile of the myocardium in these regions. I/R= Ischemia/reperfusion 
, S1P= sphingosine-1-phosphate, bar = 500µm C) Representative images of 
syndecan-1 staining of sections from one left ventricle per group show that Control 
and S1P perfused hearts have intense staining of larger blood vessels and 
capillaries, compared to minimal to mild staining observed in the I/R and I/R+S1P 
groups. Although not all blood vessels types are shown in each of the figures, a 
similar staining intensity of syndecan-1 was noted in arteries, veins and capillaries 




Chromogenic staining of cardiac sections (PFA-fixed/Paraffin-embedded sections) 
was used for assessing the presence of syndecan-1 in blood vessels.  Qualitatively, 
the staining intensity was markedly greater in non-ischemic groups (control and S1P) 
compared to that of the ischemic groups (I/R and I/R+S1P) (the outer wall of the left 
ventricle is shown in Figures 7B and 7C). The regions close to the periphery of the 
ventricular wall (epicardial and endocardium) show a greater staining intensity than 
the central ventricular wall (Figure 7B). However, when observed at higher 
magnification these regions appear to have a greater density of capillaries per unit 
area due to the cross-sectional plane of the myocardium at these peripheries and are 
not related to increased staining intensity of Syndecan-1 compared to larger blood 
vessels (not shown).  No differential staining intensity of Syndecan-1 was observed 
between arteries, veins and capillaries within each of the groups, i.e. blood vessels 
were generally of similar staining intensity within each group.  
 
Semiquantitiative analysis based on ordinal data from the scoring system used was 
not analysed statistically due to the low number of hearts (n=3 per group), however 
the patterns observed supported the qualitative analysis.  The intensity of syndecan-
1 immunostaining was decreased in the ischemic group (0.66 ± 0.04) in comparison 
to the control group (2.56 ± 0.03). Treatment with S1P before ischemia (I/R+S1P) had 
no effect on syndecan-1 intensity compared to the I/R group (0.56 ± 0.03). Syndecan-
1 intensity in hearts treated with S1P without ischemia (S1P) was not majorly different 
to control hearts but was markedly higher than groups that underwent ischemia with 





This study aimed to explore whether the known cardioprotective effect of S1P in isolated 
rat hearts during I/R injury was mediated via the stabilization of the endothelial glycocalyx. 
The results showed that S1P treatment of the isolated rat heart subjected to I/R injury led 
to a significant decrease in infarct size without an effect on shedding of coronary vascular 
syndecan-1. 
In the current study, S1P protected the heart against I/R injury, as was demonstrated by 
a decrease in infarct size. However, there was no accompanying change in hemodynamic 
recovery. The effect of S1P on the infarct size in this study was consistent with other 
studies which used the same dose of S1P 11 indicating that S1P (at a concentration of 10 
nM) was effective in reducing the infarction. These results are similar to some other 
studies that also reported decreases in infarct size without changes in the functional 
recovery when various drugs were tested. 11,31  
The filtering capacity of the endothelial barrier was determined by measuring heart TWC 
and the NFR. There was no significant difference in heart TWC between control and 
ischemic hearts. This finding is consistent with other studies investigating wet-to-dry 
weight ratio after 15 minutes ischemia and 20 minutes reperfusion32. However, the finding 
that S1P treatment alone led to a significantly decreased TWC is quite interesting. Others 
have previously shown in the guinea pig that perfusion with Krebs buffer alone leads to 
increased wet-to-dry weight ratio of the heart 33 and TWC 34 and so our finding may 
suggest that S1P treatment minimizes any edema caused by perfusion with Krebs buffer. 
The histological assessment of cardiac edema showed a different picture, wherein 
extracellular area was increased by ischemia. The difference in edema between control 
and I/R reported from the histology data is low (only 6%) and can be explained by the 
difference in timing of the two measurements; hearts for measurement of TWC were 
collected after 30 minutes reperfusion whereas hearts for histological analysis were 
collected after 60 minutes reperfusion.  Although not statistically significant our 
histological results indicated a decreased post -ischemic myocardial edema in S1P 
pretreated hearts.  These results are consistent with those of Straus Straus [35] which 
indicated that S1P may act to decrease post-ischemic myocardial edema. Possible 
reasons for the decrease in extracellular edema seen in our study could include S1P 
induced changes in hemodynamic function but lack of a difference in coronary blood flow 
between ischemic groups may suggest that hemodynamic changes are not the cause of 
the decreased extracellular edema in this case.  
The increase in the NFR shortly after reperfusion in the ischemic groups compared to the 
S1P group may indicate an increase in endothelial permeability. However, similar 
differences in NFR were not seen between the ischemic groups and the control group 
and may be due to lower NFR in the S1P-treated hearts shortly after reperfusion. It should 
be noted that the overall protocol seemed to elicit an increase in NFR compared to 
baseline levels in all groups, however this increase was not significant in S1P treated 
groups. This, together with the significant decrease in TWC in S1P treated hearts 
compared to control hearts, may suggest that S1P is eliciting some protection over 
endothelial permeability. This result is similar to a study that tested the effect of S1P on 
intact vessels and found that S1P maintains normal vascular permeability by maintaining 
the endothelial barrier in intact microvessels. 36 Furthermore, another study by Zeng et 
al37 found that S1P can stabilize the glycocalyx in cultured rat fat-pad endothelial cells in 
presence of plasma albumin, and the S1P concentration used in this study was higher 
than used in the study by Zeng et al.  
 
In order to clarify the effect of the S1P on endothelial barrier integrity and cardiac edema, 
further work may include repeats of histological analysis accompanied by some 
modification in the methods, such as adding albumin to K-H perfusate to avoid using 
crystalloid K-H which has low oncotic pressure. In addition, measuring microvascular 
permeability by using Evan-blue dyed albumin to quantify colloid protein extravasation 
could be carried out. 
The misalignment between the histological results and the heart TWC measurements 
may be related to the method itself. Some studies have suggested that histological 
assessment is more specific and more accurate in determination of edema compared 
with desiccation methods such as measurement of TWC and wet-to-dry-weight ratio. 
Moreover, it can give adequate preservation of fluid accumulation which allows for 
distinguishing between extracellular and intracellular edema, a distinction that cannot be 
made with desiccation methods alone. 34,38,39  However, in this study, only the extracellular 
edema was measured. The intracellular edema was not evident and thus not measurable, 
either because the cells were not severely damaged due to the short ischemic duration 
used in this study, or possibly the intracellular edema resolved after reperfusion as 
indicated by other studies which showed that intracellular edema is an ischemic event 
and resolved after reperfusion.40-43 
The results of this study show that I/R increased the release of syndecan-1 in the coronary 
effluent, and this may indicate glycocalyx damage. This result was consistent with other 
studies which also demonstrated that I/R caused damage to the glycocalyx and leads to 
release of its components into the circulation. 12,44,45 These findings are also consistent 
with the NFR results described above and may suggest increased endothelial 
permeability at 5 minutes of reperfusion. In this study, treatment with S1P before ischemia 
had no effect on syndecan-1 release and suggests that S1P may not protect the heart via 
stabilization of the glycocalyx. However, it is possible that S1P protects via other 
components of glycocalyx, such as heparan sulphate and hyaluronic acid. Several other 
studies testing the protective effect of drugs on the glycocalyx have measured two or 
more components of glycocalyx 15,26 because some drugs can stabilize one component 
without any effect on the other components. It is also possible that the timepoint used or 
the concentration of S1P used in the current study was too low to protect the glycocalyx. 
In this study, S1P was only administered before ischemia, whereas syndecan-1 shedding 
occurs during both ischemia and reperfusion 46. Therefore, administration of S1P at 
reperfusion may have a different effect on syndecan-1 release. In terms of the 
concentration of S1P used, Zeng et al.21 found the protective level of S1P in cultured rat 
fat-pad endothelial cells ranged from 0.2 µM to 1 µM even when there is no protein carrier 
for S1P, which is above the concentration used in this study. In addition, immuno-staining 
images of syndecan-1 assessment in coronary vessels supported the ELISA results 
revealing decreased syndecan-1 after I/R, and similar decreases in syndecan-1 staining 
in ischemic S1P treated hearts. In any case, the results of this study indicate that S1P, at 
a concentration that decreased infarct size, did not significantly decrease the elevated 
level of syndecan-1 in coronary effluent in ischemic hearts suggesting that this 
cardioprotective dose of S1P had no effect on the syndecan-1 shedding.  
A novel feature of this study was the measurement of syndecan-1 in the cardiac effluent 
of the isolated heart of rats with global ischemia. Most other studies using isolated 
perfused hearts to investigate the effects of ischemia reperfusion on the glycocalyx have 
been carried out using guinea pig hearts. A recent study attempted to assess the role of 
the glycocalyx in I/R in the mouse heart, however, the levels of syndecan-1 released in 
response to I/R were too low to measure. 47 The ability to measure syndecan-1 release 
in response to I/R in the rat heart opens up several possibilities for research on this 
important structure during I/R. Firstly, it will allow assessment of syndecan-1 shedding 
during I/R in various well characterized rat disease models. Secondly, it will allow further 
delineation of the pathways involved in protection of the glycocalyx since species specific 
antibodies are more widely available for rats than for guinea pigs. Finally, while studies 
using guinea pig hearts have provided a wealth of information on the ability of certain 
pharmacological agents to protect the glycocalyx during I/R, the large collateral supply to 
the heart of guinea pigs means that these studies have focused on global ischemia. Rat 
hearts have much less collateral circulation 48 and so it is easier to induce regional 
ischemia in isolated rat hearts. Therefore, the rat model used in our study may open the 
possibility to test the ability of pharmacological agents to protect the glycocalyx during 
regional ischemia.              
There are some limitations to this study. Firstly, some studies have shown that 
glycocalyx breakdown is initiated by perfusion with K-H buffer in the absence of 
albumin27,49. In line with this, our study showed some syndecan-1, although minimal, 
was found in the coronary effluent of control hearts. However, despite any shedding 
caused by perfusion with K-H buffer, further shedding was seen as a result of I/R, and 
S1P treatment was unable to decrease this shedding. We were worried that DMSO 
treatment in control groups might have caused glycocalyx shedding. However, in 
preliminary experiments in which syndecan-1 release from hearts perfused with K-H 
alone were measured, similar values of syndecan-1 were found compared to the control 
(p=n.s vs. control, vs. S1P perfusion).  Secondly, separation of the hearts from the 
whole animal in the Langendorff perfusion technique removes the hormonal and neural 
effect on the heart and thus may reduce the clinical relevance of our study. An 
alternative view here is that this separation of local effects from systemic effects allows 
for an understanding of the effect of treatments on cardiomyocytes, endothelial cells 
and fibroblasts alone without the complication of systemic inputs. Furthermore, one 
might also argue that preconditioning and global ischemia are more relevant to cardiac 
transplant, a condition where the heart would not be innervated 50. Thirdly, a heart 
perfused on the Langendorff system may deteriorate in contractile function at 
approximately 5–10% per hour 23,24. Since all hearts were treated the same, one would 
expect that they would deteriorate at the same rate and therefore any differences are 
due to the ischemia reperfusion insult and/or the treatment protocols. Finally, despite 
studies in Langendorff perfused hearts mimicking some of the pathophysiological 
changes seen in human myocardial infarction51 , it must be conceded that translation of 
findings from this model have not been very successful thus far and further work 
extending these findings to both in vivo and ex vivo models including comorbidities 
associated with myocardial infarction are needed. 52 
 
This study showed that I/R leads to increased infarct size, increased release of syndecan-
1 in the coronary effluent and histological changes. S1P treatment protects the heart 
against I/R injury, as was indicated by the decreased infarct size. The fact that S1P 
pretreatment had no effect on the shedding of syndecan-1, indicates that any such 
protection is not mediated by maintenance of syndecan-1 in the glycocalyx. It is possible 
that S1P at this concentration may protect the glycocalyx by stabilizing other glycocalyx 
components that were not measured in the present study. The study opens up prospects 
of investigating the role of the glycocalyx in the rat heart, including the more clinically 
relevant regional I/R model.  
Perspectives: This study demonstrated that S1P induced cardioprotection is not 
mediated by maintenance of syndecan-1 in the endothelial glycocalyx. It also 
demonstrates for the first time that syndecan-1 levels in the coronary effluent of perfused 
rat hearts increase in response to ischemia reperfusion injury.  
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